Catalyst Pharmaceuticals, Inc. clinical trials
Acquired by Angelini Pharma, Jul 15, 2026 · source ↗
The registry lists 13 studies whose lead sponsor is Catalyst Pharmaceuticals, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 24, 2026.
Before and after it joined Angelini Pharma
- First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- 13
- First submitted after Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Catalyst Pharmaceuticals, Inc.13 studies
Something wrong with this grouping? Tell us on the Angelini Pharma page.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. All Angelini Pharma studies →
- Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMITRecruitingNCT06564974
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic SyndromeApproved for marketingNCT02189720
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)TerminatedNCT03579966Phase 3
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MGCompletedNCT03304054Phase 3
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3TerminatedNCT03819660Phase 2
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 PatientsCompletedNCT03781479Phase 2
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- A Safety, Tolerability and Pharmacokinetic Study of CPP-115CompletedNCT01493596Phase 1
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- Amifampridine Phosphate for the Treatment of Congenital Myasthenic SyndromesCompletedNCT02562066Phase 3
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine DependenceTerminatedNCT00730522Phase 2
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)CompletedNCT02970162Phase 3
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)CompletedNCT01377922Phase 3
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- Vigabatrin for the Treatment of Cocaine DependencyCompletedNCT01281202Phase 2/3
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma
- Vigabatrin for Treatment of Cocaine DependenceCompletedNCT00611130Phase 2
Sponsor listed in the registry: Catalyst Pharmaceuticals, Inc. · First submitted before Catalyst Pharmaceuticals, Inc. became part of Angelini Pharma